Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis.

Kushan KarunaratneDariush AhrabianBernadette MonoghanTom CampionTarek YousryMichael P T LunnMichael S ZandiRobin S HowardDimitri M KullmannJennifer SpillaneMatthew WalkerJeremy Chataway

Published in: BMJ neurology open (2021)

Our case provides further class IV evidence of the use of bortezomib therapy for treatment refractory anti-NMDAR encephalitis.

Keyphrases

multiple sclerosis
multiple myeloma
white matter